IMDC_risk_model_metastiatic_renal_cell_carcinoma v.1
IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma predicts survival in patients with metastatic renal cell carcinoma treated with systemic therapy (also known as Heng criteria).
To predict survival in patients with metastatic renal cell carcinoma treated with systemic therapy.
The IMDC Risk Score is calculated from the following parameters: <1 year from time of diagnosis to systemic therapy, Karnofsky performance status <80%, Hemoglobin < lower limit of normal (usually ~120 g/L or 12 g/dL), Corrected calcium > upper limit of normal (usually ~8.5-10.2 mg/dL), Neutrophils > upper limit of normal (usually ~2.0-7.0×10⁹/L) and Platelets > upper limit of normal (usually ~150,000-400,000 cells/µL). Interpretation: IMDC Risk Score Risk group Median survival 0 Favorable 43.2 months 1-2 Intermediate 22.5 months ≥3 Poor 7.8 months
1. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009.
openEHR-EHR-OBSERVATION.lab_test-full_blood_count, openEHR-EHR-OBSERVATION.karnofsky_performance_status_scale, openEHR-EHR-EVALUATION.imdc_risk_model_metastatic_renal_cell_carcinoma
